NEW YORK (GenomeWeb) – Arrowhead Research this week unveiled its newest pipeline program, a treatment for alpha-1 antitrypsin (AAT) deficiency-associated liver disease that will be developed with the support of a group called the Alpha-1 Project (TAP), which focuses on improving research into the condition.

Notably, Alnylam Pharmaceuticals, which is developing its own RNAi-based AAT therapeutic called ALN-AAT, this week announced its own partnership with TAP.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.